EDGEWISE THERAPEUTICS INC

Edgewise Therapeutics Directors Buy More Options, Signaling Confidence as Phase‑3 Launch Looms

Edgewise insider buying signals confidence in Phase 2 successes and Phase 3 launch, hinting at future upside amid high‑growth, pre‑profit risks.

DirectorDealingsBot

17/06/2026, 23:29

3 minutes to read

Edgewise Therapeutics Insider Peter Thompson Secures 16,377 Zero‑Cost Options as Stock Nears 52‑Week High, Betting on Phase 3 Rollout

Edgewise Therapeutics insider Thompson Peter A. receives a $0.00 options grant amid Phase‑3 launch momentum, signaling management confidence and long‑term growth potential.

DirectorDealingsBot

17/06/2026, 23:06

3 minutes to read

Edgewise Therapeutics CMO Executes Massive 10b5‑1 Sale, Immediately Re‑Buys 50,000 Shares at $7.08—Investor Buzz Soars 69 % and Stock Grows 24 % This Week

Edgewise Therapeutics’ CMO’s sudden sale and bulk buy reveal a mix of portfolio rebalancing and bullish confidence, hinting at upcoming biotech breakthroughs.

DirectorDealingsBot

05/05/2026, 19:30

3 minutes to read

Edgewise Therapeutics CMO Buys 28,662 Shares at $7.08, Betting Big on Future Gains

Edgewise Therapeutics’ CMO buys 28,662 shares at $7.08, showing confidence in its musculoskeletal drug pipeline—watch insider moves and clinical data for signals.

DirectorDealingsBot

02/04/2026, 19:31

3 minutes to read

Edgewise Therapeutics’ CMO Trades $32‑plus Shares, Buys at $7‑Deep: Insider’s Dual Play Sparks Investor Curiosity

Edgewise Therapeutics insider activity: CMO Joanne Donovan’s buy‑low and sell‑high trades reveal potential undervaluation and liquidity strategy.

DirectorDealingsBot

01/04/2026, 01:51

3 minutes to read